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Purpose
This paper overviews the nationwide cancer statistics including incidence, mortality, survival
and prevalence, and their trends in Korea based on the year 2008 cancer incidence data. 
Materials and Methods
Incidence data from 1993 to 2008 were obtained from the Korea National Cancer Incidence
Database, and the vital status was followed through December 31, 2009. Mortality data from
1983 to 2008 were obtained from the Korea National Statistics Office. Crude rates and age-
standardized rates for incidence, mortality, prevalence and relative survival were calculated.
Results
There were 178,816 cancer cases and 68,912 cancer deaths observed during year 2008 and
724,663 10-year cancer prevalent cases as of January 1, 2009 in Korea. The incidence rate
for all cancer combined showed an annual increase of 3.1% from 1999 to 2008.
Conclusion
With significantly increasing cancer incidence, Korea faces a large cancer burden and
efficient cancer control programs are essential.
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I n t r o d u c t i o n
Cancer has been the leading cause of death in Korea since 1983 [1]
and has drawn much attention in public health. Over 170,000 new
cancer cases are diagnosed annually in Korea and one out of four
deaths results from cancer [2,3]. This paper gives an overview of the
nationwide cancer statistics, including the incidence, mortality,
prevalence, survival rates and their trends in Korea. 
1   Data sources
The Ministry of Health and Welfare, Korea had initiated a nation-
wide hospital-based cancer registry as early as 1980 called the Korea
Central Cancer Registry (KCCR). The registry collected appro-
ximately 80-90% cancer cases from more than 150 training hospitals
pISSN 1598-2998│eISSN 2005-9256
across the country every year. From 1999, the KCCR expanded cancer
registration to cover the whole population under the Population-Based
Regional Cancer Registry (PB-RCR) program. Details of the history,
objectives, and activities of the KCCR have been documented [4].
Incidence data from 1999 to 2008 were obtained from the Korea
National Cancer Incidence Database (KNCI DB). Cancer cases were
classified according to the International Classification of Diseases for
Oncology 3rd edition [5] and converted according to the International
Classification of Diseases 10th edition (ICD-10) [6]. The survival
analysis used 1,623,046 cancer cases first diagnosed during 1993-2008
from the KNCI DB, and followed the vital status through 31 December
2009.
Mortality data from 1983 to 2008 were obtained from the Korea
National Statistics Office (KNSO) [1]. Cause of death was coded and
classified according to the ICD-10. The population data were also
obtained from KNSO using the resident registration population on July
1st of specified years.
A n a l y s i s
Crude rates (CRs) and age-specific rates of cancer incidence and
mortality were calculated. Age-standardized rates (ASRs) were deter-
mined using the World Health Organization (WHO) world standard
population [7]. The cumulative risks of cancer incidence, which
represent the probability of developing cancer to life expectancy, were
also calculated. Changes in the annual age-standardized cancer
incidence rates were examined by calculating the annual percentage
change over a time period as (exp(b)-1)x100, where b is the slope of
the regression of log ASR on a calendar year [8].
In order to assess the level of cancer burden, prevalence was also
estimated which represents new and pre-existing cancer cases
diagnosed during a given period of time and still alive on an index date.
Using the cancer incidence database from 1999 to 2008, we calculated
the limited-duration prevalence, such as 1, 5, and 10-year prevalence.
In this study, for example, 10-year prevalence was calculated from the
number of people alive on January 1, 2009 who were diagnosed with
cancer within the previous 10 years. We applied the counting method
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Sites
New cases Deaths 10-yr prevalent casesa)
Both sexes Male Female Both sexes Male Female Both sexes Male Female
All sites 178,816 93,017 85,799 68,912 43,785 25,127 724,663 334,329 390,334 
Lip, oral cavity, 2,557 1,899 658 969 761 208 11,304 7,728 3,576
and pharynx
Esophagus 2,181 1,986 195 1,385 1,244 141 5,216 4,717 499 
Stomach 28,078 18,898 9,180 10,312 6,712 3,600 134,722 89,616 45,106 
Colon and rectum 22,623 13,536 9,087 6,802 3,809 2,993 103,033 60,448 42,585 
Liver 15,663 11,776 3,887 11,292 8,512 2,780 36,036 27,085 8,951 
Gallbladderb) 4,378 2,149 2,229 3,459 1,698 1,761 9,935 5,076 4,859 
Pancreas 4,320 2,404 1,916 3,767 2,135 1,632 4,780 2,663 2,117 
Larynx 1,073 998 75 409 364 45 6,385 5,977 408 
Lung 18,774 13,384 5,390 14,791 10,899 3,892 34,926 23,465 11,461 
Breast 12,659 75 12,584 1,731 13 1,718 79,468 381 79,087 
Cervix uteri 3,888 - 3,888 954 - 954 33,102 - 33,102 
Corpus uteri 1,562 - 1,562 210 - 210 9,084 - 9,084 
Ovary 1,816 - 1,816 834 - 834 9,732 - 9,732 
Prostate 6,471 6,471 - 1,168 1,168 - 23,940 23,940 -
Testis 176 176 - 14 14 - 1,408 1,408 -
Kidney 3,228 2,220 1,008 655 461 194 15,243 10,265 4,978 
Bladde 3,230 2,582 648 1,007 752 255 18,260 14,845 3,415 
Brain and CNS 1,620 876 744 1,040 568 472 6,273 3,289 2,984 
Thyroid 26,923 4,275 22,648 347 108 239 107,693 15,252 92,441 
Hodgkin lymphoma 210 127 83 46 31 15 1,253 796 457 
Non-Hodgkin lymphoma 3,475 1,936 1,539 1,343 814 529 16,142 8,873 7,269 
Multiple myeloma 893 480 413 615 316 299 2,464 1,295 1,169 
Leukemia 2,561 1,432 1,129 1,507 867 640 9,936 5,442 4,494 
Other and ill-defined 10,457 5,337 5,120 4,255 2,539 1,716 44,328 21,768 22,560 
Table 1.  Number of cancer incidence cases, deaths, and prevalent cases by sex during 2008 in Korea 
CNS, central nervous system. a)10-yr prevalent cases: limited-duration prevalent cases on January 1, 2009. These are patients that were diagnosed between January 1, 1999 and
December 31, 2008 and were alive on January 1, 2009. Multiple primary cancer cases were counted multiple times, b)Includes gallbladder and other/unspecified parts of biliary tract. 
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using SEER*Stat software [9] to calculate the number of prevalent
cases while adjusting for the patients lost in follow-up [8]. 
The survival duration of each case was determined as the time
difference between the date of initial diagnosis and the date of death,
date of loss to follow-up, or closing date for follow-up. Observed sur-
vival rates were calculated using a life table method and relative sur-
vival rates were examined with the Ederer II method [10] using an al-
gorithm written in SAS by Dickman [11], with some minor modi-
fications. 
S e l e c t e d  F i n d i n g s
1   Incidence
Table 1 presents the overall number of cancer incident cases, deaths
and prevalent cases during 2008 in Korea by sex and cancer site. In
2008, 178,816 cancer incident cases and 68,912 deaths were observed
in Korea. As of January 1, 2009, there were 724,663 10-year cancer
prevalent cases observed in Korea. The cumulative risks for develo-
ping cancer to the life expectancy were 37.2% for men and 30.5 for
women in 2008.
Table 2 shows the cancer incidence rates by sex in 2008. The CRs of
all sites combined in 2008 were 375.7 and 348.1 per 100,000 in men
and women, respectively. The ASRs of all sites combined were 318.5
and 245.3 per 100,000 in men and women, respectively. In males, the
five leading primary sites of cancer were the stomach (CR, 76.3; ASR,
63.8), colon and rectum (CR, 54.7; ASR, 45.9), lung (CR, 54.1; ASR,
46.9), liver (CR, 47.6; ASR, 38.9), and prostate (CR, 26.1; ASR, 23.0),
accounting for 68.9% of all newly diagnosed cancers in 2008. In
females, the most common cancer sites were the thyroid (CR, 91.9;
ASR, 68.6), breast (CR, 51.1; ASR, 36.8), stomach (CR, 37.2; ASR,
24.9), colon and rectum (CR, 36.9; ASR, 24.7), lung (CR, 21.9; ASR,
13.9), and cervix uteri (CR, 15.8; ASR, 11.2), accounting for 73.2% of
all newly diagnosed cancers. Thyroid cancer alone accounted for
26.4% (22,648) of incident cases in women in 2008.
2   Mortality
There were 68,912 cancer deaths reported in Korea during 2008,
accounting for 28.0% of all deaths (Table 3). In 2008, The CRs of all
Sites
Crude incidence rates/100,000 Age-standardized incidence rates/100,000a)
Both sexes Male Female Both sexes Male Female
All sites 361.9 375.7 348.1 271.1 318.5 245.3 
Lip, oral cavity, and  pharynx 5.2 7.7 2.7 3.9 6.4 1.9 
Esophagus 4.4 8.0 0.8 3.3 6.9 0.5 
Stomach 56.8 76.3 37.2 42.2 63.8 24.9 
Colon and rectum 45.8 54.7 36.9 34.1 45.9 24.7 
Liver 31.7 47.6 15.8 23.7 38.9 10.5 
Gallbladderb) 8.9 8.7 9.0 6.4 7.5 5.5 
Pancreas 8.7 9.7 7.8 6.3 8.3 4.8 
Larynx 2.2 4.0 0.3 1.6 3.4 0.2 
Lung 38.0 54.1 21.9 27.7 46.9 13.9 
Breast 25.6 0.3 51.1 18.7 0.3 36.8 
Cervix uteri 7.9 - 15.8 5.8 - 11.2 
Corpus uteri 3.2 - 6.3 2.4 - 4.6 
Ovary 3.7 - 7.4 2.8 - 5.5 
Prostate 13.1 26.1 - 9.6 23.0 -
Testis 0.4 0.7 - 0.4 0.7 -
Kidney 6.5 9.0 4.1 5.0 7.4 3.0 
Bladder 6.5 10.4 2.6 4.7 9.0 1.6 
Brain and CNS 3.3 3.5 3.0 2.9 3.3 2.6 
Thyroid 54.5 17.3 91.9 40.8 13.1 68.6 
Hodgkin lymphoma 0.4 0.5 0.3 0.4 0.5 0.3 
Non-Hodgkin lymphoma 7.0 7.8 6.2 5.5 6.7 4.6 
Multiple myeloma 1.8 1.9 1.7 1.4 1.6 1.2 
Leukemia 5.2 5.8 4.6 5.0 5.7 4.3 
Other and ill-defined 21.2 21.6 20.8 16.5 19.1 4.3 
Table 2.  Crude and age-standardized cancer mortality rates by sex during 2008 in Korea
CNS, central nervous system. a)Age adjusted to the World Health Organization (WHO) world standard population, b)Includes gallbladder and other/unspecified parts of biliary tract.
sites combined were 176.9 and 101.9 per 100,000 for men and women,
respectively. The ASRs of all sites combined were 154.1 and 63.5 per
100,000 for men and women, respectively. Cancers of the lung, liver,
stomach and colon and rectum were the most common fatal cancers,
which accounted for about 62.7% of all cancer deaths in 2008 (Table 4).
In men, the five leading primary cancer sites for mortality in 2008
were the lung (CR, 44.0; ASR, 38.7), liver (CR, 34.4; ASR, 28.5),
stomach (CR, 27.1; ASR, 23.5), colon and rectum (CR, 15.4; ASR,
13.5), and pancreas (CR, 8.6; ASR, 7.5). In women, lung cancer mor-
tality (CR, 15.8; ASR, 9.4) increased gradually being the first cancer
site for mortality in 2008, followed by stomach (CR, 14.6; ASR, 8.7),
colon and rectum (CR, 12.1; ASR, 7.3), liver (CR, 11.3; ASR, 7.2),
and gallbladder (CR, 7.1; ASR, 4.1).
3   Trends in cancer incidence
Tables 5-7 present the cancer incidence rates during 1999-2008 in
Korea for all sites combined and for selected cancer sites. The
incidence rate for all sites combined increased by 3.1% annually from
1999 to 2008. The incidence rate for all sites combined increased by
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Sites
Crude mortality rates/100,000 Age-standardized mortality rates/100,000a)
Both sexes Male Female Both sexes Male Female
All sites 139.5 176.9 101.9 101.0 154.1 63.5 
Lip, oral cavity, and pharynx 2.0 3.1 0.8 1.4 2.6 0.5 
Esophagus 2.8 5.0 0.6 2.1 4.4 0.3 
Stomach 20.9 27.1 14.6 14.8 23.5 8.7 
Colon and rectum 13.8 15.4 12.1 9.8 13.5 7.3 
Liver 22.9 34.4 11.3 16.9 28.5 7.2 
Gallbladderb) 7.0 6.9 7.1 4.9 6.1 4.1 
Pancreas 7.6 8.6 6.6 5.5 7.5 4.0 
Larynx 0.8 1.5 0.2 0.6 1.3 0.1 
Lung 29.9 44.0 15.8 21.3 38.7 9.4 
Breast 3.5 0.1 7.0 2.6 0.0 4.9 
Cervix uteri 1.9 - 3.9 1.4 - 2.5 
Corpus uteri 0.4 - 0.9 0.3 - 0.6 
Ovary 1.7 - 3.4 1.2 - 2.3 
Prostate 2.4 4.7 - 1.6 4.6 -
Testis 0.0 0.1 - 0.0 0.1 -
Kidney 1.3 1.9 0.8 1.0 1.6 0.5 
Bladder 2.0 3.0 1.0 1.4 2.8 0.5 
Brain and CNS 2.1 2.3 1.9 1.7 2.0 1.4 
Thyroid 0.7 0.4 1.0 0.5 0.4 0.5 
Hodgkin lymphoma 0.1 0.1 0.1 0.1 0.1 0.0 
Non-Hodgkin lymphoma 2.7 3.3 2.1 2.0 2.8 1.4 
Multiple myeloma 1.2 1.3 1.2 0.9 1.1 0.8 
Leukemia 3.1 3.5 2.6 2.6 3.2 2.0 
Other and ill-defined 8.6 10.3 7.0 6.3 9.1 4.4 
Table 4.  Crude and age-standardized cancer mortality rates by sex during 2008 in Korea
CNS, central nervous system. a)Age adjusted to the World Health Organization (WHO) world standard population, b)Includes gallbladder and other/unspecified parts of biliary tract. 
Table 3. Ten leading causes of death during 2008 in Korea
Cause of No. of Percent of
Age-
Rank
death deaths all deaths
standardized 
death ratea)
All causes 246,113 100.0 365.3 
1        Cancer 68,912 28.0 101.0 
2        Cerebrovascular 27,932 11.3 39.1 
disease
3        Heart disease 21,429 8.7 30.6 
4        Intentional self 12,858 5.2 20.3
harm (suicide)
5        Diabetes mellitus 10,234 4.2 14.5 
6        Chronic lower 7,338 3.0 10.1 
respiratory diseases 
7        Transport accidents 7,287 3.0 12.1 
8        Disease of liver 7,164 2.9 10.7 
9        Pneumonia 5,461 2.2 7.7 
10        Hypertensive diseases 4,724 1.9 6.6  
Others 72,774 29.6 112.6 
Source: Mortality Data, 2008, Korea National Statistical Office. a)Age adjusted to the
World Health Organization (WHO) world standard population. 
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Sites
Year
APCa)
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
All sites 210.5 205.1 216.7 220.1 227.1 234.1 246.7 250.5 260.8 271.1 3.1b)
Lip, oral cavity, and pharynx 3.6 4.4 3.6 3.7 3.8 3.8 3.8 3.7 3.8 3.9 0.1
Esophagus 4.1 3.7 3.9 3.8 3.6 3.5 3.5 3.4 3.3 3.3 -2.1b)
Stomach 43.6 42.3 44.0 43.6 43.2 41.1 44.3 42.7 41.6 42.2 -0.3
Colon and rectum 20.4 21.0 22.9 24.7 26.8 28.5 30.8 32.2 33.3 34.1 6.4b)
Liver 27.9 26.7 27.3 26.5 25.7 25.5 25.8 24.5 24.2 23.7 -1.7b)
Gallbladderc) 6.5 6.4 6.7 6.7 6.7 6.9 7.1 6.6 6.5 6.4 0.1
Pancreas 5.6 5.5 5.5 5.8 5.8 6.0 6.3 6.1 6.3 6.3 1.7
Larynx 2.3 2.2 2.4 2.2 2.1 1.9 2.0 1.8 1.8 1.6 -3.9b)
Lung 28.5 27.7 28.3 28.5 27.8 28.7 28.9 28.6 28.2 27.7 0.0
Breast 10.7 10.8 12.7 13.9 14.2 14.9 16.1 16.8 17.9 18.7 6.5b)
Cervix uteri 8.5 7.9 8.3 7.7 7.4 6.8 6.5 6.3 5.7 5.8 -4.6b)
Corpus uteri 1.4 1.3 1.5 1.7 1.9 1.9 2.0 2.1 2.1 2.4 6.0b)
Ovary 2.7 2.5 2.5 2.6 2.7 2.7 2.8 2.8 3.0 2.8 1.6b)
Prostate 3.1 2.7 3.6 3.9 4.8 5.9 6.3 7.2 8.5 9.6 15.2b)
Testis 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.4 0.4 0.4 3.5b)
Kidney 3.0 2.9 3.3 3.4 3.5 3.7 4.1 4.4 4.7 5.0 6.4b)
Bladder 4.6 4.6 4.9 4.7 5.1 5.1 5.1 4.9 4.9 4.7 0.5
Brain and CNS 2.9 2.8 2.8 2.6 2.9 2.9 3.1 2.9 3.1 2.9 1.0b)
Thyroid 6.3 6.1 7.9 9.5 12.7 17.2 20.6 25.3 32.6 40.8 25.1b)
Hodgkin lymphoma 0.2 0.3 0.3 0.3 0.3 0.4 0.3 0.3 0.4 0.4 4.5b)
Non-Hodgkin lymphoma 4.5 4.2 4.5 4.6 4.9 5.2 5.3 5.5 5.5 5.5 3.3b)
Multiple myeloma 1.0 1.0 1.1 1.1 1.1 1.2 1.3 1.3 1.4 1.4 4.0b)
Leukemia 4.7 4.3 4.7 4.8 4.7 4.8 4.7 4.9 4.8 5.0 0.9b)
Other and ill-defined 14.3 13.5 13.9 13.5 15.1 15.1 16.0 15.9 16.8 16.5 -
Table 5.  Trends in cancer incidence rates in both sexes during 1999-2008 in Korea
CNS, central nervous system. a)Annual percent change (APC) using age-standardized incidence based on the World Health Organization (WHO) world standard population, b)The
APC is significantly different from zero (p＜0.05), c)Includes gallbladder and other/unspecified parts of biliary tract.
Sites
Year
APCa)
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
All sites 285.0 276.7 288.3 290.0 294.2 298.6 310.4 308.6 314.3 318.5 1.5b)
Lip, oral cavity, and pharynx 6.1 7.1 6.0 6.2 6.5 6.1 6.0 6.1 6.2 6.4 -0.4
Esophagus 8.8 8.0 8.3 8.2 7.7 7.7 7.6 7.2 6.9 6.9 -2.5b)
Stomach 66.2 65.0 67.2 66.6 65.9 62.2 66.7 65.2 62.8 63.8 -0.5
Colon and rectum 26.2 27.2 29.6 32.9 35.2 37.8 40.9 43.0 44.8 45.9 7.0b)
Liver 46.8 44.7 45.1 43.9 42.3 42.1 42.6 40.1 39.5 38.9 -1.9b)
Gallbladderc) 8.1 7.8 8.2 8.1 7.8 8.4 8.7 8.1 7.9 7.5 -0.2
Pancreas 7.8 7.6 7.6 7.9 7.7 8.0 8.3 8.0 8.2 8.3 0.9b)
Larynx 4.9 4.5 5.1 4.7 4.4 4.1 4.3 3.7 3.7 3.4 -3.8b)
Lung 51.4 49.8 51.1 51.0 49.9 50.8 50.8 49.1 48.5 46.9 -0.7b)
Breast 0.2 0.3 0.2 0.3 0.2 0.2 0.2 0.2 0.1 0.3 -2.2
Prostate 8.4 7.2 9.5 10.1 12.3 15.0 15.7 17.8 20.7 23.0 13.7b)
Testis 0.6 0.5 0.6 0.6 0.6 0.6 0.6 0.7 0.7 0.7 3.4b)
Kidney 4.5 4.4 4.9 5.0 5.2 5.5 6.0 6.5 7.0 7.4 6.0b)
Bladder 9.0 9.0 9.4 9.0 9.7 9.8 9.7 9.5 9.3 9.0 0.3
Brain and CNS 3.2 3.1 3.1 2.9 3.3 3.3 3.4 3.2 3.4 3.3 0.9
Thyroid 2.1 1.9 2.4 2.7 3.7 4.8 5.9 7.5 9.9 13.1 24.5b)
Hodgkin lymphoma 0.4 0.4 0.4 0.3 0.4 0.5 0.4 0.4 0.5 0.5 2.8
Non-Hodgkin lymphoma 5.8 5.5 5.8 5.8 6.2 6.6 6.4 6.8 6.9 6.7 2.5b)
Multiple myeloma 1.2 1.3 1.4 1.4 1.4 1.4 1.6 1.4 1.6 1.6 3.1b)
Leukemia 5.5 5.0 5.4 5.8 5.4 5.7 5.5 5.6 5.6 5.7 0.8
Other and ill-defined 17.9 16.5 16.8 16.5 18.4 18.1 19.1 18.6 19.9 19.1 -
Table 6. Trends in cancer incidence rates in males during 1999-2008 in Korea
CNS, central nervous system. a)Annual percent change (APC) using age-standardized incidence based on the World Health Organization (WHO) world standard population, b)The
APC is significantly different from zero (p＜0.05), c)Includes gallbladder and other/unspecified parts of biliary tract.
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1.5% annually in men and by 5.1% in women from 1999 to 2008. The
rapid increase in cancer incidence is also illustrated in Fig. 1.   
As shown in Fig. 2, the incidence rates have continued to increase
for colon and rectum and thyroid cancer in both sexes, along with
breast cancer in females and prostate cancer in males. On the contrary,
the incidences of liver cancer in both sexes and cervix cancer in
women have decreased. Stomach cancer incidence rates remained the
same in men and women. One notable aspect was the sharp increase
(25.4% annually) in the incidence of female thyroid cancer. As diagno-
stic techniques for thyroid cancer have become more sensitive, such as
with the advent of ultrasound and fine-needle aspiration, the detection
of subclinical disease has become possible. Therefore, the increased
incidence of thyroid cancer may reflect improved diagnostic tech-
niques for previously undetected disease, rather than a true increase in
the occurrence of thyroid cancer [12,13]. Furthermore, from the con-
struction of a KNCI DB for 1999 onward to 2008, the completeness of
the Korea cancer registry data has improved gradually. This might
have contributed in part to the gradual overall increase in cancer
incidence, especially among the elderly. 
4   Age-specific incidence rates for selected cancer sites
Table 8 presents the most common cancer sites by sex and age
group in 2008. Leukemia and thyroid were the most common forms in
both sexes, for ages 0-14 and 15-34 years, respectively. For males,
Sites
Year
APCa)
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
All sites 161.1 157.4 169.0 174.6 183.8 192.8 206.7 215.0 229.7 245.3 5.1b)
Lip, oral cavity, and pharynx 1.6 2.4 1.7 1.7 1.7 1.8 1.9 1.8 1.9 1.9 0.5
Esophagus 0.6 0.6 0.6 0.5 0.6 0.5 0.4 0.5 0.5 0.5 -2.2b)
Stomach 26.7 25.2 26.2 26.3 25.9 24.7 26.8 25.0 24.7 24.9 -0.6
Colon and rectum 16.4 16.4 17.9 18.8 20.4 21.4 22.8 23.9 24.2 24.7 5.3b)
Liver 12.3 11.8 12.2 11.8 11.5 11.3 11.3 11.1 11.0 10.5 -1.5b)
Gallbladderc) 5.3 5.5 5.7 5.8 5.8 5.9 6.0 5.5 5.6 5.5 0.2
Pancreas 4.0 4.0 4.0 4.2 4.4 4.4 4.7 4.7 4.7 4.8 2.5b)
Larynx 0.4 0.3 0.3 0.3 0.3 0.3 0.3 0.2 0.2 0.2 -9.0b)
Lung 12.4 12.5 12.3 12.6 12.4 13.0 13.5 13.9 13.8 13.9 1.5b)
Breast 20.9 20.9 24.7 27.2 27.8 29.1 31.7 33.1 35.4 36.8 6.7b)
Cervix uteri 16.3 15.1 15.8 14.8 14.2 13.1 12.4 12.2 11.0 11.2 -4.5b)
Corpus uteri 2.8 2.6 3.0 3.3 3.8 3.7 3.9 4.0 4.2 4.6 6.2b)
Ovary 5.0 4.8 4.8 5.0 5.1 5.2 5.4 5.4 5.8 5.5 1.8b)
Kidney 1.7 1.8 1.9 2.0 2.1 2.2 2.5 2.7 2.8 3.0 6.5b)
Bladder 1.6 1.6 1.7 1.7 1.8 1.7 1.7 1.6 1.7 1.6 -0.1
Brain and CNS 2.6 2.5 2.5 2.4 2.5 2.7 2.8 2.7 2.8 2.6 1.0
Thyroid 10.4 10.1 13.2 16.2 21.7 29.5 35.2 43.0 55.2 68.6 25.4b)
Hodgkin lymphoma 0.1 0.2 0.2 0.2 0.2 0.2 0.2 0.3 0.3 0.3 7.1b)
Non-Hodgkin lymphoma 3.4 3.2 3.4 3.5 3.9 4.1 4.4 4.3 4.3 4.6 4.2b)
Multiple myeloma 0.8 0.8 0.9 0.8 1.0 1.0 1.2 1.1 1.2 1.2 5.3b)
Leukemia 3.9 3.8 4.1 4.0 4.1 4.1 4.0 4.3 4.1 4.3 1.1b)
Other and ill-defined 11.8 11.5 11.8 11.5 12.6 12.9 13.7 13.9 14.4 14.3 -
Table 7. Trends in cancer incidence rates in females during 1999-2008 in Korea
CNS, central nervous system. a)Annual percent change (APC) using age-standardized incidence based on the World Health Organization (WHO) world standard population, b)The
APC is significantly different from zero (p < 0.05), c)Includes gallbladder and other/unspecified parts of biliary tract. 
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Rank
Age (yr)
0-14 15-34 35-64 ≥65
Males
1 Leukemia (4.5) Thyroid (8.2) Stomach (92.1) Lung (447.5)
2 Brain and CNS (2.3) Leukemia (3.3) Liver (69.5) Stomach (443.6)
3 Non-Hodgkin lymphoma (1.4) Stomach (2.9) Colon and rectum (64.5) Colon and rectum (323.3)
4 Kidneya) (0.5) Colon and rectum (2.7) Lung (41.4) Prostate  (245.3)
5 Testisa) (0.5) Non-Hodgkin lymphoma  (2.4) Thyroid (30.0) Liver  (211.6)
Females
1 Leukemia (3.7) Thyroid (44.5) Thyroid (166.0) Colon and rectum  (161.9)
2 Brain and CNS (1.9) Breast (9.2) Breast (98.8) Stomach (154.0)
3 Non-Hodgkin lymphoma (0.9) Cervix uteri (5.3) Stomach (40.9) Lung (117.7)
4 Thyroid (0.7) Stomach (4.4) Colon and rectum (39.0) Liver (74.5)
5 Ovary (0.7) Ovary (2.7) Cervix uteri (24.2) Thyroid (69.3)
Table 8. Five major sites of cancer incidence by age group and sex during 2008 in Korea
CNS, central nervous system. a)Kidney and testis are same rank.
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Fig. 2. Trend of age-standardized cancer incidence for selected cancers by sex during 1999-2008 in Korea. Age-standardization was based on the
World Health Organization (WHO) world standard population. (A) Male. (B) Female.
stomach cancer was the most common in 35-64-year-olds, while lung
cancer was more frequent for patients aged 65 and over. Thyroid
cancer was the most common site for mid-aged Korean women (35-
64-year-olds), and colorectal cancer was the most common among old
aged women (≥65 year-olds). 
Fig. 3 shows the age-specific incidence rates of the selected cancers
for men and women in 2008. The data show that the incidence of
stomach, lung, liver and colorectal cancers increased gradually with
age. Female breast and thyroid cancers showed highest incidence rates
for women in their late forties and early fifties, respectively, and then
leveled off. This pattern is very different from the rates observed in
Western countries [14].
5   Trends in cancer mortality
Figs. 1 and 4 show the trends in cancer deaths for all sites combined
and for selected cancer sites. Age-standardized mortality rates have
decreased for all sites combined in both sexes since 2002. Lung cancer
surpassed stomach cancer as the leading cause of cancer death in 1999,
and is expected to account for 21.5% of all cancer deaths in 2008. The
age-standardized mortality rates of lung have decreased slightly for
men since 2001, but increased in women. The age-standardized mor-
tality rates of stomach and cervix uteri cancer have decreased
continuously. Along with the significant increases in colorectal, pro-
state and female breast cancer incidence, the mortality rates of these
cancers have also continued to increase.
6   Survival rates
Table 9 shows the 5-year relative survivals for four periods of
diagnosis time: 1993-1995, 1996-2000, 2001-2005 and 2004-2008.
Cancer patients that were diagnosed in the recent period (2004-2008)
had 5-year relative survival rates of 59.5% for all sites combined in
both sexes, 50.8% in males and 69.2% in females. When compared
with earlier periods, notable improvements have been observed in the
5-year relative survival rates for all sites combined. Observation of
higher female cancer survival rates than male cancer survival rates may
be partly explained by common female cancers (e.g., thyroid, breast,
and uterine cervix) that are known to have relatively good prognoses.
When examined by the year of diagnosis and cancer site, the 5-year
relative survival rates appeared to be higher for most major cancer sites
in patients diagnosed during 2004-2008 compared to 1993-1995,
except for pancreatic cancer. The greatest improvements were seen in
prostate, stomach, leukemia, and non-Hodgkin lymphoma. The
improving survival rates could be attributable to early detection, as well
as to improved treatments [15,16], but this needs to be evaluated
further. Lack of progress in early detection and treatment could explain
the observed absence of improvement in the survival rate of pancreatic
cancer [17].
7   Prevalence rates
Table 10 shows the 10-year cancer prevalent rates on January 1,
2009 in Korea by sex and cancer site. The 10-year cancer prevalence
CRs of all sites combined were 1,350.4 and 1,583.7 per 100,000 in
men and women, respectively, and the 10-year cancer prevalence
ASRs of all sites combined were 1,145.0 and 1,136.2 per 100,000 in
men and women, respectively. In males, the five leading primary sites
of cancer for prevalence were the stomach (CR, 362.0; ASR, 302.0),
colon and rectum (CR, 244.2; ASR, 206.1), liver (CR, 109.4; ASR,
90.2), prostate (CR, 96.7; ASR, 86.3), and lung (CR, 94.8; ASR, 81.1),
accounting for 67.2% of all cancer prevalent cases. In females, the
most common cancer sites were the thyroid (CR, 375.1; ASR, 277.7),
breast (CR, 320.9; ASR, 232.2), stomach (CR, 183.0; ASR, 123.6),
colon and rectum (CR, 172.8; ASR, 115.8), cervix uteri (CR, 134.3;
ASR, 95.1), and lung (CR, 46.5; ASR, 31.2), accounting for 77.8% of
all cancer prevalent cases.
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Sites
Crude mortality rates/100,000 Age-standardized mortality rates/100,000a)
Both sexes Male Female Both sexes Male Female
All sites 1,466.8 1,350.4 1,583.7 1,107.4 1,145.0 1,136.2 
Lip, oral cavity, and pharynx 22.9 31.2 14.5 17.4 25.8 10.5 
Esophagus 10.6 19.1 2.0 8.0 16.4 1.3 
Stomach 272.7 362.0 183.0 203.2 302.0 123.6 
Colon and rectum 208.5 244.2 172.8 155.1 206.1 115.8 
Liver 72.9 109.4 36.3 56.0 90.2 25.9 
Gallbladderb) 20.1 20.5 19.7 14.8 17.5 12.9 
Pancreas 9.7 10.8 8.6 7.2 9.0 5.8 
Larynx 12.9 24.1 1.7 9.7 20.8 1.0 
Lung 70.7 94.8 46.5 52.8 81.1 31.2 
Breast 160.9 1.5 320.9 118.5 1.3 232.2 
Cervix uteri 67.0 - 134.3 49.1 - 95.1 
Corpus uteri 18.4 - 36.9 13.9 - 27.2 
Ovary 19.7 - 39.5 15.4 - 30.4 
Prostate 48.5 96.7 - 34.6 86.3 -
Testis 2.8 5.7 - 2.6 5.2 -
Kidney 30.9 41.5 20.2 23.9 34.2 15.0 
Bladder 37.0 60.0 13.9 26.9 51.8 8.6 
Brain and CNS 12.7 13.3 12.1 11.6 12.4 10.8 
Thyroid 218.0 61.6 375.1 163.1 47.1 277.7 
Hodgkin lymphoma 2.5 3.2 1.9 2.2 2.8 1.7 
Non-Hodgkin lymphoma 32.7 35.8 29.5 26.1 30.5 22.3 
Multiple myeloma 5.0 5.2 4.7 3.8 4.4 3.3 
Leukemia 20.1 22.0 18.2 20.0 22.0 18.1 
Other and ill-defined 89.7 87.9 91.5 71.1 78.0 65.7 
Table 10. Crude and age-standardized cancer 10-yr prevalent rates on January 1, 2009 by sex during 2008 in Korea
CNS, central nervous system.  a)Adjusted to the World Health Organization (WHO) world standard population, b)Includes gallbladder and other/unspecified parts of biliary tract.
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Fig. 5. Number of prevalent cases by
time since diagnosis for major cancer
sites on January 1, 2009 in Korea.
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Fig. 5 shows the prevalence by time since diagnosis. For all cancers
combined, the 1- to 2-year prevalence represented 37% of the total
prevalent cases. The 1- to 2-year prevalence as a percentage of the total
was highest for thyroid cancer (18%) following stomach (16%), and
colorectal cancer (14%), which has high incidence rates and a good
prognosis. For all cancers combined, the 2- to 5-year prevalence and
the 5- to 10-year prevalence constituted 33% and 30% of the total
prevalence in both sexes, respectively. The long-term prevalence of
lung and liver cancer was relatively low due to lower rates of survival.
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